Join the Oncology Voice Network. Join for Free
MSL Visibility - How to SUCCEED in 2024
Medical Science Liaisons MSL effectiveness MSL visibility MSL strategies Eleonora Goldberg

MSL Visibility - How to SUCCEED in 2024


Share This Article


Summary

Tom Caravela welcomes Eleonora Goldberg to explore the evolving role of Medical Science Liaisons (MSLs) within organizations. They delve into the key attributes leaders seek in MSLs and share strategies for standing out and enhancing team performance. Essential skills for MSL effectiveness and methods for evaluating performance are discussed, alongside preparing for industry changes and maintaining positivity in 2024. Eleonora offers predictions and expresses optimism for the future of MSLs. The episode concludes with closing remarks, appreciation, and a reminder to subscribe and stay engaged.

My guest this week is Eleonora Goldberg, Vice President, Medical Affairs at Arrowhead Pharmaceuticals and we discuss MSL Visibility and how to succeed in 2024.

 Eleonora shares….

πŸ‘‰ What is the VALUE of MSLs
πŸ‘‰ What leaders look for in MSLs
πŸ‘‰ How can MSLs separate themselves from their peers
πŸ‘‰ How might 2024 be different for MSLs
πŸ‘‰ What advice is there for dealing with uncertainty

Click for Source
Medical Science Liaisons, MSL effectiveness, MSL visibility, MSL strategies, Eleonora Goldberg

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Social Media Listening Evolved
Partner Avatar MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson

Social Media Listening Evolved

Podcast
How to Start Presenting Like a Pro
Partner Avatar MSL Talk: Tom Caravela

How to Start Presenting Like a Pro

Article
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
OVN Avatar Michael Z. Liao, Dan Lu, Matts KΓ₯gedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li

Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?

Podcast
MSL Career Options: The transition from Field Medical to Medical Director
Partner Avatar MSL Talk: Tom Caravela, Josh Corriveau

MSL Career Options: The transition from Field Medical to Medical Director

Article
Cancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled Trials
OVN Avatar Shubham Sharma, J Connor Wells, Wilma M Hopman, Joseph C Del Paggio, Bishal Gyawali, Nazik Hammad, Annette E Hay, Christopher M Booth

Cancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled Trials

Article
CheckMate-067: Raising the Bar for the Next Decade in Oncology
OVN Avatar Sarah A. Weiss, MD, and Harriet Kluger, MD

CheckMate-067: Raising the Bar for the Next Decade in Oncology

Explore OVN